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patients were analyzed to identify subgroups of patients regarding potential for DDI 
and antipsychotic treatment costs. RESULTS: Of 8221 schizophrenia patients identi-
ﬁ ed in the data base 28.2% had co-prescriptions with potential for DDI and were 
regarded as subgroup for well directed use of PER. The average antipsychotic costs/
quarter of these patients were €399.0/patient for atypicals; €276.5/patient for generic
and €613.2/patient for patent protected atypicals (incl. PER). The average treatment 
costs/quarter for PER were 551.0 EUR/patient. PER treatment of all patients treated 
with patent protected atypicals at risk for DDI would reduce the overall antipsychotic
expenditure for schizophrenia by 1.9%. PER treatment of all atypical patients 
with potential DDI would increase the schizophrenia antipsychotics budget by 
8.0%. CONCLUSIONS: The budgetary impact of well directed used PER is limited
by the share of schizophrenia patients with potential DDI. As PER is associated with 
10% lower treatment costs compared to patent protected atypicals, PER could reduce
costs if used instead of other patent protected atypicals. Reduced risk for DDI com-
plications with PER may lead to additional cost savings that are not captured in this 
analysis.
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OBJECTIVES: To investigate the costs of dementia in Hungary, analyzing the distribu-
tion of direct and indirect costs, considering also the costs of caregivers. On basis of 
prevalence estimations from previous dementia studies we extrapolated the mean cost
issues and estimated the burden of dementia for the population aged 50 in Hungary. 
METHODS: A cross-sectional study of 88 consecutive patients with dementia and
their caregivers was conducted in 2008 involving physicians and nurses of 3 GP and
1 outpatient practices. Resource Utilization in Dementia (RUD), Mini Mental State
Examination (MMSE), and the health related quality of life EuroQoL (EQ-5D) ques-
tionnaires were applied. Using 2007 prices we established the proportion of the main
cost-drivers and categorized cost-data by patients’ age and MMSE scores. RESULTS:
Patients (59% female) were involved with clinical characteristics of mean MMSE 16.7
(SD 7.24), EQ-5D 0.401 (SD 0.327.), 59% were female, mean age was 78 years (SD 
8.5). The average monthly direct costs per patient were 282 (SD 532) euros, mean
indirect costs were 53 (SD 187) euros/patient/month. Total costs by age-groups (total
sample, 65–74, 75–84 and 85 or more years) considering mental status (MMSE score 
level of 0–18, 19–24 and 25–30) within each were 176, 234, 108, 131 and 375, 588,
166, 67 and 418, 569, 262, 121 euros/patient/month, respectively. Dementia-related 
health services and indirect costs (income loss of caregivers) had the highest shares of 
the whole, 32%–32%for both. CONCLUSIONS: Costs of increase by age and severity
of the disease (measured by MMSE scores). At national level, in 2008 the estimated
direct costs of dementia were 255 million euros with 48 million euros indirect costs. 
Trends show a remarkable growth in the number of the demented patients. Therefore,
an increase of disease burden of dementia is expected in the future.
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OBJECTIVES: To compare, through cost-beneﬁ t analysis, a long-acting atypical anti-
psychotic (risperidone) with two second-generation oral antipsychotics (olanzapine
and clozapine) and a “typical” prolonged action antipsychotic (pipotiazine).
METHODS: We designed a decision tree that included only direct costs, from the 
third party payer perspective and a single year time frame. Main epidemiological
variables, obtained mostly from international literature and clinical trials, were adher-
ence, relapses with and without hospitalization, and side effects. Local costs were 
obtained from Colombian health insurers and providers. RESULTS: According to the
model, the use of long acting risperidone injection was associated with the lowest 
overall costs to the system (US$5169 per year) followed closely by clozapine (US$5221) 
whose long term metabolic effects were not included in the model. Either one of these
drugs would save around US$ 800 per year when compared with olanzapine
(US$6087), and more than US$1000 when compared with pipotiazine (US$6544), the 
least expensive of the group and currently the standard of care in most patient groups.
CONCLUSIONS: Despite their apparent higher costs, atypical antipsychotics can be 
cost saving through their reduction in relapses and hospitalizations. The economic
beneﬁ t, particularly with risperidone injection which had the lowest side effects, would
be added to the direct and indirect beneﬁ ts to the patients and their communities due 
mainly to relapse reduction.
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OBJECTIVES: Bipolar disorder has an associated economic burden due to its treat-
ment, including medication and hospitalization costs as well as costs associated with
treatment of comorbid medical conditions. This study compared health care costs in 
patients treated with a mood stabilizer and adjunctive aripiprazole versus adjunctive 
olanzapine, quetiapine, risperidone or ziprasidone. METHODS: A retrospective 
propensity score-matched cohort study was conducted in the LabRx integrated
claims database from January 2003 through December 2006. Patients aged 18–65 
years with bipolar disorder and 180 days of pre-index enrolment without atypical
antipsychotic therapy and 90 days post-index enrolment were eligible for inclusion.
Mood stabilizer therapy was initiated prior to index atypical prescription. Generalized
gamma regressions were used to compare the total health care costs of patients 
treated with adjunctive aripiprazole and patients treated with adjunctive olanzapine, 
quetiapine, risperidone or ziprasidone. RESULTS: After controlling for differences in 
baseline characteristics and pre-index cost, psychiatric costs and subtotal psychiatric 
and general medical cost were signiﬁ cantly higher for all adjunctive atypical antipsy-
chotics than adjunctive aripiprazole (p  0.001). There was no signiﬁ cant difference
in general medical costs between aripiprazole and ziprasidone, olanzapine, or quetiap-
ine. Aripiprazole medication costs were signiﬁ cantly higher than for quetiapine and 
risperidone (p  0.001) but not olanzapine or ziprasidone. Total health care costs
were signiﬁ cantly higher for ziprasidone, olanzapine, or risperidone (p  0.001) than 
aripiprazole but not for quetiapine. CONCLUSIONS: Adjunctive aripiprazole may 
have economic beneﬁ ts over other atypical antipsychotics in terms of lower psychiatric 
treatment costs of care than adjunctive olanzapine, quetiapine, risperidone or ziprasi-
done, and lower total health care costs than adjunctive olanzapine, risperidone or
ziprasidone.
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OBJECTIVES: The objective of this study was to compare the health care utilization 
and associated cost in a group of schizophrenia and schizoaffective patients pre and 
post risperidone long-acting injection (RLA) treatment. METHODS: This was a ret-
rospective cost analysis study. Data was gathered solely from hospital records, which 
were reviewed for data pertaining to utilization of health care resources. The study
was performed from a public health care institute’s perspective. Patients studied were
from three public hospitals in Hong Kong. They were started on antipsychotic treat-
ment but later on switched to RLA therapy due to adverse effects, poor response or 
whatever reasons and remained on risperidone for a minimum of 12 months. The 
initial RLA administration date served as the index date. Study periods included 12-
month pre and 24-month post the index date and patients served as their own control.
Cost data collected included medications, laboratory procedures, other more sophis-
ticated investigational procedures (e.g. CT, MRI), regular and extra outpatient clinic 
visits, emergency room utilization, hospitalization, and other health services such as 
special counseling sessions. RESULTS: A total of 180 patients who received RLA
treatment were identiﬁ ed from 2 public general and 1 psychiatric hospitals in Hong 
Kong over the period of 2003–2006. The overall annual cost of treatment before and
after RLA injection was HKD80.5 million (USD10.3 million; 1USD  7.8HKD) and 
HKD26 million (USD3.34 million) respectively. The annual average cost per patient 
before and after RLA treatment was HKD447,300 (USD57,300) and HKD144,600 
(USD18,500) respectively. CONCLUSIONS: From the present group of patients 
assessed two years after initiation of RLA treatment, it appears that the treatment can 
potentially lead to substantial cost savings. The major cost driver appears to be hos-
pitalization due to either poor control or adverse effects of medications.
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OBJECTIVES: First-line treatment of MDD patients with a generic SSRI is often 
encouraged by managed care organizations. However, some patients may require 
second line therapy. This study evaluates the economic consequences associated with 
three options of second-line treatment: escitalopram, an SNRI (venlafaxine or dulox-
etine), or a generic SSRI. METHODS: Adult MDD patients treated with a generic 
SSRI were identiﬁ ed in the Ingenix Impact database (2003–2007) and included if they 
switched to escitalopram, an SNRI, or another generic SSRI. Urgent care utilization
during the 3-month follow-up was compared across these three study cohorts. Costs 
incurred during three months pre- vs. post-switching date were compared descriptively 
and using regression analyses adjusting for patient demographics, comorbidities, prior
resource use and length of therapy. RESULTS: The study identiﬁ ed 7,774 switchers 
to escitalopram, 10,505 to SNRIs, and 6,723 to a generic SSRI. Compared to escitalo-
pram switchers, patients who switched to an SNRI or a generic SSRI had an increased
adjusted risk of mental health-related urgent care utilization (OR  1.30 and 1.17 
respectively, both P  0.05). Patients who switched to escitalopram had a $402 reduc-
tion in medical costs (P  0.001) during the 3-month follow-up period compared to
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baseline costs, while switchers to an SNRI had a $254 reduction. However, switchers 
to a generic SSRI had a $99 increase in medical costs. Controlling for baseline char-
acteristics, escitalopram switchers had the highest total health care cost reduction of 
the three groups, with $383 (P  0.016) in savings relative to SNRI switchers and
$172 (P  0.276) in savings relative to switchers to a generic SSRI. CONCLUSIONS:
MDD patients requiring second line therapy who switched to escitalopram had sig-
niﬁ cantly lower urgent care utilization than patients switching to an SNRI or another 
generic SSRI. Using escitalopram as second-line therapy appears to be a cost saving
strategy compared to using SNRIs or generic SSRIs.
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OBJECTIVES: Antidepressants may alleviate insomnia in depressed patients. The
effects of antidepressants may be delayed, however, with potentially adverse effects
on compliance and persistence, health care costs, and work loss. We sought to assess
whether early treatment of insomnia improves outcomes and reduces costs in patients 
initiating antidepressants. METHODS: Retrospective cohort study of persons initiat-
ing anti-insomnia medications a1 year after initiating antidepressants in health-
insurance claims database (50 million members covered by large US employers, 
years 2002–2006). Patients initiating anti-insomnia medications a3 weeks after 
initiation of antidepressants (“early treatment”) were matched to patients initiating 
anti-insomnia medications 3–52 weeks after initiation of antidepressants (“late treat-
ment”) based on propensity scores and other baseline characteristics and compared
in terms of compliance, therapy switching, health care utilization and costs, and
days and employer costs of paid absences during 1 year follow-up. RESULTS: Early
and late-treated patients (n  4976 pairs) were well matched on baseline characteristics
including age (both 44 years, p  .5696), sex (34% and 35%, p  .3523), class of 
initial anti-depressant (SSRIs 77% for both), comorbidities, and pre-index health
care utilization and costs. Compared with those receiving late treatment with anti-
insomnia medications, those receiving early treatment were less likely to switch
antidepressants (30% vs. 40%, p  .0001), had fewer physicians ofﬁ ce visits (mean
[SD] 8.5 [9.7] vs. 9.9 [10.2], p  .0001), were less likely to have hospitalizations/
emergency department visits (34% vs. 39%, p  .0001), and had lower health care
costs during follow-up (mean [SD] $9,152 [$24,769] vs. $10,587 [$22,078], p 
0.0020). Among patients with paid absence data (n  56 pairs), early treated patients
had fewer paid absence hours (mean [SD] 153 [107] vs. 254 [317], p  0.0322) and 
lower employer paid absence costs (mean [SD] $3780 [$2669] vs. $6296 [$7893], p
 0.0328). CONCLUSIONS: Early and appropriate treatment for insomnia may
reduce frequency of switching of antidepressant therapy and lower health care and
employer costs.
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OBJECTIVES: This study examines, from a U.S. health care perspective, the cost-
effectiveness of olanzapine long-acting injection (OLAI) compared to risperidone
long-acting injection, haloperidol decanoate, and oral olanzapine in the treatment of 
schizophrenia patients who are nonadherent with oral antipsychotics. METHODS: A
1-year microsimulation economic decision model was developed to simulate the 
dynamic usual care of schizophrenia patients who may switch, continue, discontinue, 
and restart medications. The model captures clinical and cost parameters including
adherence levels, relapse with and without hospitalization, quality adjusted life years 
(QALYs), treatment discontinuation by reason, treatment-emergent adverse events, 
suicide, health care resource utilization, and direct medical care costs. Published 
medical literature, unpublished data, and a clinical expert panel were used to develop
baseline model assumptions. Key model outcomes included annual total direct cost 
per treatment, cost per stable patient, and incremental cost-effectiveness values per 1
QALY gained. RESULTS: OLAI was found to have an incremental cost of $60,273/
QALY over haloperidol decanoate. OLAI dominated all other comparators by produc-
ing more QALYs and fewer inpatient relapses (dominant over RLAI) or by producing 
more QALYs and fewer inpatient relapses with a lower incremental cost-effectiveness 
ratio (extended dominance over oral olanzapine). The base case and multiple sensitiv-
ity analyses found OLAI to be a cost-effective option in terms of incremental cost/
QALY gained. Results were most sensitive to change in the cost of relapse. CONCLU-
SIONS: OLAI is projected in this microsimulation model to be a cost-effective treat-
ment option for a costly, complex, and challenging group of patients – nonadherent 
schizophrenia patients – by yielding more QALYs and fewer inpatient relapses than
each comparator and providing a cost-effective option in terms of incremental cost 
per QALY gained.
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OBJECTIVES: Agomelatine is the ﬁ rst melatonergic antidepressant approved by the 
European Medicine Agency for the treatment of major depressive disorder (MDD) in 
adults. The objective of our study was to perform a cost-effectiveness analysis for
agomelatine based on clinical trials against placebo and venlafaxine from a Swedish 
societal perspective. METHODS: We developed a Markov model with health states
for well, depressive episode, remission and death. The model also incorporated sleep 
disorders, discontinuation rates, discontinuation symptoms and adverse drug reactions 
(incl. constipation, diarrhoea, dyspepsia, headache, nausea, somnolence and sexual
dysfunction). The time horizon was set to two years. Relapse and discontinuation rates
were estimated using Weibull regressions, while remission rates were estimated
directly. Costs and utilities for different health states were taken from a Swedish 
observational study. Frequencies of adverse events, sleep disorders and discontinuation
symptoms were taken from three relevant trials, while costs and disutilities were esti-
mated from the literature. Costs (reported in EUR 2008) and effects were discounted 
at 3% per year. RESULTS: In the base case, agomelatine is cost-saving and more 
effective than venlafaxine and placebo. One-way sensitivity analyses showed that the 
results were robust to most parameter changes. At a willingness-to-pay threshold of 
€50,000 per quality-adjusted life year gained, agomelatine was cost-effective compared 
to venlafaxine in 96% of the cases in the probabilistic sensitivity analysis. CONCLU-
SIONS: Based on data from clinical trials and the literature, our results indicate that 
agomelatine is cost-saving and more effective than venlafaxine in treating MDD in 
Sweden. These results are robust, conﬁ rmed by sensitivity analysis.
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OBJECTIVES: Of the various subtypes of anxiety disorders, generalized anxiety dis-
order (GAD) is the most frequent, lifetime prevalence 6.2%, and is connected with
relevant economic and societal consequences. The aim of this study was to assess the 
cost-effectiveness of pregabalin in the treatment of GAD from an institutional perspec-
tive. METHODS: We developed a three-state Markov model to simulate health and 
economic outcomes during a time horizon of one-year (12-week cycles). The model 
includes several stages related to disability (complete response, partial response and 
relapse). Effectiveness was assumed as the percentage of patients with complete
response at the end of the follow-up period using the Hamilton Anxiety Rating Scale 
(HAM-A) (50% reduction related to baseline score) and a Clinical Global Impression
of Improvement (CGI-I) score of 1 or 2. Transition probabilities were obtained
from a meta-analysis involving international published trials. Comparators used in 
the assessment were paroxetine (10–40 mg/day); venlafaxine (75–225 mg/day) and 
pregabalin (300–450 mg/day). Resource use and costs were obtained from 4,000 
randomized hospital records from the Social Security Mexican Institute (IMSS). 
Costs included outpatient and inpatient services, drug, procedures, etc. The model
was calibrated. Probabilistic sensitivity analyses were performed employing boots-
trapping techniques and acceptability curves were constructed. RESULTS: The 
highest percentage of patients with complete response to the HAM-A scale during 
the follow-up period was obtained by pregabalin (39.8%; CI95% 38.5%–41.1%), 
followed by venlafaxine (22.6%; CI95% 21.9%–23.4%) and paroxetine (16.5%;
CI95% 16.0%–17.0%). Regarding the CGI-I the highest percentage for complete 
response was for pregabalin (35.3%; CI95% 34.2%–36.5%); followed by venla-
faxine (28.8%; CI95% 27.8%–29.7%) and paroxetine (16.6%; CI95% 16.1%–
17.2%). The annual expected mean costs per patient were US$1,893.1
(US$1,830.7–US$1955.4), US$2001.2(US$1935.3–US$2067.2) and US$955.1(US$923.6–
US$986.5). The ICER for pregabalin vs. paroxetine (baseline) was US$4019.7
(US$3887.3–US$4153.7) for HAM-A and US$5017.9(US$4852.6–US$5183.2) for 
CGI-I. Second-order Monte Carlo sensitivity analyses showed that pregabalin was a
cost-effective therapy (p  0.05). CONCLUSIONS: Pregabalin showed to be a cost-
effective therapy due to its higher efﬁ cacy response in the management of GAD.
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OBJECTIVES: Recognition and understanding of generalized anxiety disorder (GAD) 
have expanded in recent years. GAD is associated with high use of health care 
resources, predominantly primary care, and its economic burden on society is consid-
erable. The objective of this study was to assess the cost-effectiveness of current
treatments for GAD from the payer’s perspective. METHODS: We developed a micro-
simulation model to estimate costs and effectiveness during a time horizon of 12 
weeks. Effectiveness was assumed as the percentage of patients with complete response
at the end of the follow-up period using the Hamilton Anxiety Rating Scale (HAM-A) 
–over 50% reduction related to baseline score- and Quality Adjusted Life Years
